KOSP Kos Pharmaceuticals

Kos Pharmaceuticals, Inc. (Nasdaq:KOSP), a fully integrated specialty pharmaceutical company, will announce results for the third quarter ended September 30, 2006, before the market opens on Thursday, November 9, 2006. Following the release, Kos� senior management will host a conference call at 8:30 a.m. ET to discuss the Company�s results. The conference call will be available live via the Internet by accessing Kos� website at www.kospharm.com. Please go to the website at least fifteen minutes prior to the call to register, download and install any necessary audio software. Those who cannot access the webcast can dial into the conference call at 913-981-4911 confirmation code 6981451. A replay will also be available on the website at www.kospharm.com or by calling 888-203-1112 domestic or international, and entering 6981451 from 2:00 PM ET on November 9, 2006 until 12:00 AM ET on November 16, 2006. If you would like to receive notices and news regarding Kos, please visit the Investor Relations section of the Company website and subscribe to email alerts. Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a particular focus on the cardiovascular, metabolic and respiratory disease areas. The Company�s principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, and patient compliance. Kos� strategy also includes making measured investments in new chemical entity research through in-house and sponsored research, scientific in-licensing and general corporate development activities. The Company currently markets Niaspan�, Advicor�, Azmacort�, Cardizem�LA, Teveten� and Teveten�HCT. Kos Pharmaceuticals, Inc. (Nasdaq:KOSP), a fully integrated specialty pharmaceutical company, will announce results for the third quarter ended September 30, 2006, before the market opens on Thursday, November 9, 2006. Following the release, Kos' senior management will host a conference call at 8:30 a.m. ET to discuss the Company's results. The conference call will be available live via the Internet by accessing Kos' website at www.kospharm.com. Please go to the website at least fifteen minutes prior to the call to register, download and install any necessary audio software. Those who cannot access the webcast can dial into the conference call at 913-981-4911 confirmation code 6981451. A replay will also be available on the website at www.kospharm.com or by calling 888-203-1112 domestic or international, and entering 6981451 from 2:00 PM ET on November 9, 2006 until 12:00 AM ET on November 16, 2006. If you would like to receive notices and news regarding Kos, please visit the Investor Relations section of the Company website and subscribe to email alerts. Kos Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company engaged in developing, commercializing, manufacturing and marketing proprietary prescription products for the treatment of chronic diseases with a particular focus on the cardiovascular, metabolic and respiratory disease areas. The Company's principal product development strategy is to reformulate existing pharmaceutical products with large market potential to improve safety, efficacy, and patient compliance. Kos' strategy also includes making measured investments in new chemical entity research through in-house and sponsored research, scientific in-licensing and general corporate development activities. The Company currently markets Niaspan(R), Advicor(R), Azmacort(R), Cardizem(R)LA, Teveten(R) and Teveten(R)HCT.